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Jlpha-Adrenergic Coronary
asoconstriction in Humans
read with interest the study of Jensen et al. (1) and the
ccompanying editorial (2). Jensen et al. demonstrated the abun-
ance of the 1D-adrenoceptor subtype on the mRNA and by
adioligand binding on the protein level in epicardial coronary
rteries of explanted healthy and diseased human hearts. This
nformation is novel and potentially important for the development
f more specific -adrenoceptor blockers to treat hypertension
nd/or prostate hyperplasia. The accompanying editorial correctly
mphasizes the importance of studies in human rather than animal
issue. The original study and the editorial, however, do not
cknowledge the limitations of the in vitro nature of the study.
pecifically, no information on the morphological and/or func-
ional status of the analyzed coronary arterial segment with respect
o its underlying atherosclerosis is provided. In fact, mRNA and
adioligand binding of an adrenoceptor in vitro are one thing, but
heir functional contribution to coronary blood flow in vivo is a
ifferent thing. The original study and the editorial do not
cknowledge that: 1) coronary blood flow in humans is tightly
egulated by redundant mechanisms such that -adrenergic vaso-
onstriction has little impact under physiological conditions; and
) microvascular 2-adrenoceptors are of greater importance than
picardial 1-adrenoceptors, particularly in the presence of coro-
ary stenoses (3). The functional importance of 2-adrenergic
oronary vasoconstriction was first demonstrated in dogs (4,5) and
ubsequently confirmed in humans in relevant clinical settings such
s percutaneous coronary intervention (6–9). Thus, in the context
f -adrenergic coronary vasoconstriction, the “in vivo over in
itro” may outweigh the “human over animal” preference; studies
n dogs are particularly suited because their coronary vascular
-adrenoceptor distribution is largely identical to that of humans
5,6). The original study and the editorial contrast human only to
ouse and rat tissue. Clearly, studies in humans in vivo are
referable, notably with respect to polymorphisms (7) and also
easible with current imaging modalities (3).
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eply
e appreciate Dr. Heusch for calling attention to our paper (1)
nd for his generous praise.
We do, however, disagree with some comments in his letter.
is letter says that we do not acknowledge the distinction between
2-adrenergic receptors (ARs) (microvascular) and 1-ARs (epi-
ardial coronaries), the fact that -vasoconstriction is limited to
rteries with coronary artery disease, and that 2-mediated coro-
ary vasoconstriction is more important than 1-mediated.
In fact, in our introduction, we state: “The 1-ARs constrict
rimarily epicardial coronary arteries and large arterioles, whereas
2-ARs act mostly on the coronary microcirculation. Stimulation
f 1-ARs by endogenous catecholamines produces little constric-
ion of normal coronary arteries, but causes pronounced vasocon-
triction in coronary arteries with atherosclerotic endothelium” (1).
n making these statements, we cite Dr. Heusch’s group (refer-
nces 3 and 6 in his letter).
In addition, in his reference 6, 1- and 2-agonists appear to
educe coronary blood flow to a similar extent in patients with
oronary artery disease (Figs. 3 and 5 in Baumgart et al. [2]),
uggesting similar 1- and 2-mediated effects in humans.
Furthermore, his letter also states that no information is
rovided “on the morphological and/or functional status of the
nalyzed coronary arterial segment with respect to its underlying
therosclerosis.” On the contrary, we did analyze 1-AR subtype
RNAs according to the presence or absence of coronary artery
isease, as determined by coronary angiography and direct
bservation, and found no significant differences (Fig. 5A in
ensen et al. [1]).
We do agree fully that in vivo coronary physiology is mostmportant. In this regard, it is highly pertinent that the 1D
